APOTHEEK LISMONDE
ActiveFrom the official registers: KBO 30 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
APOTHEEK LISMONDE has been active since 1995 and the Belgian Official Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €529,982 and a net result of €95,918. Equity has been growing by about 8% per year since 2018. Its solvency ranks better than 90% of 9,537 sector peers (NACE 47, financial year 2024). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
KBO- Status
- Active since 17-01-1995 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Establishment unit
- 2.074.115.465 2970 Schilde, since 01-12-1995
- Financial year end
- 31 December
- Peppol
- Reachable
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €391,475
- ▲ 22.5%
- Turnover
- ≈ €1.4m
- estimated
- Profit
- €95,918
- ▲ 219%
- Equity
- €529,982
- ▲ 22.1%
- Total assets
- €653,608
- ▲ 19.9%
- Staff
- 1.8 FTE
- ▼ 14.3%
Score breakdownraises riskCapped at 59: a confirmed filing findingFigures for financial year 2024 (filed on 01-09-2025)lowers riskFounded in 1995Equity €529,982 (81.1% of total assets)Liquidity: current ratio 3.86, cash €105,331Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 92% of them on solvency, 72% on liquidity, 42% on profitability and 74% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 6 accounts on average 28 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (1)
Key points
- Positive: Result rose in 2024from €30,033 to €95,918 ▲ 219% View
- Positive: Higher solvency than 90% of companies in retail tradesector median 38.3% · 9,537 companies 81.1% View
- Caution: Board changedlatest change 02-04-2026 · 1 in office 1 joined · 1 left View
- Positive: 7 profitable years in a rowprofit 2024: €95,918 7 years View
Comparable companies
These companies have the same main activity as APOTHEEK LISMONDE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €611,000 and €743,000, founded between 1994 and 2000.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK LISMONDE Schilde | €653,608 | €391,475 |
| HEIST-FARMA Heist-op-den-Berg | €610,567 | €386,411 |
| APOTHEEK DEHAENE-POUILLON Ravels | €742,901 | €422,395 |
| PHARMACIE DE L'ALLIANCE Braine-l'Alleud | €687,722 | €338,346 |
| APOTHEEK SOFIE DHONT Gavere | €692,188 | €360,858 |
| HELDO Erpe-Mere | €621,357 | €310,545 |
| PHARMACIE DE LA COLLEGIALE Nivelles | €713,579 | €415,999 |
Documents
Annual accounts at the NBB
- Annual accounts 2024filed on 28-08-2025
- Annual accounts 2023filed on 28-08-2024
- Annual accounts 2022filed on 29-08-2023
- Annual accounts 2021filed on 26-08-2022
Acts in the Belgian Official Gazette
- Resignations & appointmentsact of 02-04-2026
- Amendment of the articlesact of 30-12-2024
- Resignations & appointmentsact of 17-11-2023
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about APOTHEEK LISMONDE
- What is the company number of APOTHEEK LISMONDE?
- The company number of APOTHEEK LISMONDE is 0454.430.053. The VAT number is the same number with BE in front: BE 0454.430.053.
- Where is APOTHEEK LISMONDE based?
- The registered office is at Turnhoutsebaan 80, 2970 Schilde.Company details
- What does APOTHEEK LISMONDE do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK LISMONDE?
- The legal form of APOTHEEK LISMONDE is Public limited company (NV).
- When was APOTHEEK LISMONDE founded?
- APOTHEEK LISMONDE was founded on 17-01-1995.
- Is APOTHEEK LISMONDE still active?
- Yes, APOTHEEK LISMONDE is an active enterprise in the KBO register.
- How many employees does APOTHEEK LISMONDE have?
- APOTHEEK LISMONDE had an average of 1.8 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- What is the turnover of APOTHEEK LISMONDE?
- The turnover in financial year 2024 is ≈ €1.4m. This figure is estimated from the gross margin of €391,475 and 47 comparable companies (NACE 477). It probably lies between €1.1m and €2.3m.
- Is APOTHEEK LISMONDE profitable?
- In financial year 2024, APOTHEEK LISMONDE made a profit of €95,918.
- Where can I find the annual accounts of APOTHEEK LISMONDE?
- APOTHEEK LISMONDE filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2024.Annual accounts 2024 (PDF)
Next steps
See how customers, suppliers and banks see your own company and what to improve first.